Month: May 2020

Nes Ziona, Israel, May 07, 2020 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that an investigator-initiated multi-center Phase II clinical trial of AllocetraTM (formerly referred to as off-the-shelf AllocetraTM) in COVID-19 patients has commenced.“While work investigating the exact pathophysiology of COVID-19 is ongoing, recent publications have described the complications related to the virally induced COVID-19 disease as associated with organ dysfunction and cytokine storms, which are markedly similar to those observed in septic patients in the ICU,” said Prof. Vernon van Heerden, Head of the Critical Care Medicine Unit at Hadassah Hospital in Israel, and the lead investigator of both the COVID-19 trial and a recently-completed Phase Ib clinical trial of AllocetraTM...

TORM plc (“TORM” or the “Company”) (ticker: TRMD A on Nasdaq in Copenhagen and TRMD on Nasdaq in New York) will release its financial results for the first quarter of 2020 on Thursday, 14 May 2020.The Company’s results will be presented at a conference call at 9:00 am Eastern Time / 3:00 pm Central European Time. If you wish to participate in the call, please dial +45 3272 0417 (or +1 (646) 741 3167 for US connections) at least ten minutes prior to the start of the call to ensure connection and use 2797502 as conference ID.There will be a simultaneous live webcast via TORM’s website https://investors.torm.com. Participants should register on the website approximately ten minutes prior to the start of the webcast. ABOUT TORMTORM is one of the world’s leading carriers of refined oil products. The Company operates a fleet of approximately...

Torsdag den 14. maj 2020 offentliggør TORM plc (“TORM” eller “Selskabet”) (symbol: TRMD A på Nasdaq i København og TRMD på Nasdaq i New York) regnskabet for første kvartal 2020.Der afholdes en telekonference kl. 9.00 EST / kl. 15.00 dansk tid, hvor Selskabets resultater vil blive gennemgået. Interesserede kan deltage ved at ringe på tlf. +45 3272 0417 (eller +1 (646) 741 3167 fra USA) mindst ti minutter før telekonferencens start for at sikre forbindelse og oplyse følgende kode: 2797502.Konferencen transmitteres som live webcast via TORMs hjemmeside https://investors.torm.com. Deltagere bedes tilmelde sig på hjemmesiden ca. ti minutter før webcastets start. OM TORMTORM er en af verdens førende transportører af raffinerede olieprodukter. Rederiet driver en samlet flåde på ca. 80 moderne skibe med høje krav til sikkerhed, miljøansvar og...

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has entered into an agreement with Creapharm Clinical Supplies (“Creapharm”), a leader in clinical trial supply services, for the packaging, labelling and distribution of Phase 2 clinical trial drug product supply of its MS1819 therapy for the treatment of exocrine pancreatic insufficiency (EPI). Under the terms of the agreement, Creapharm will package, label, provide qualified person (QP) release and distribute AzurRx’s MS1819 clinical trial drug product for both the upcoming Phase 2b OPTION 2 Monotherapy and the ongoing Phase 2 Combination Therapy clinical trials for the treatment of EPI...

CINCINNATI, May 07, 2020 (GLOBE NEWSWIRE) — Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the first quarter ended March 31, 2020, and provided a business update.“We continue to be excited about our glaucoma program,” said Joseph Gardner, President and Founder.  “The statistically significant reductions in intraocular pressure (IOP) together with the favorable tolerability profile observed in the Phase 1b study in combination with standard of care prostaglandin therapy were very encouraging. We look forward to continuing to evaluate razuprotafib  in the planned 28-day Phase 2 open angle glaucoma (OAG) study which we currently expect to initiate in the third...

CINCINNATI, May 07, 2020 (GLOBE NEWSWIRE) — Protech Home Medical Corp. (the “Company”) (TSXV: PTQ), a ‎healthcare services company with operations in the U.S., today announced that it will host its Q2 2020 earnings conference call and audio webcast on Wednesday, May 20, 2020 at 10:00 a.m. (EDT).Conference Call Details:Wednesday, May 20, 2020 at 10:00 a.m. (EDT).Canada/US Toll Free: 1 (800) 319 4610International: 1 (604) 638 5340Audio Webcast Details:The live audio webcast can be found on the investor section of the Company’s website through the following link:https://www.protechhomemedical.com/conference_calls.php#“I am very pleased to offer current and future interested participants an audio webcast option, along with the standard telephone dial-in for our Q2 2020 earnings call and subsequent quarters,” said CEO and Chairman Greg...

IRVINE, Calif., May 07, 2020 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that it will release financial results for its 2020 first quarter, which ended March 31, 2020, on Tuesday, May 12, 2020 after the market close.Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-9034, or at (201) 493-6737 if calling from outside the U.S. or Canada. Callers should dial in at least 5 minutes prior to the call start time.A live and archived webcast may be accessed by visiting the company’s website at www.clearpointneuro.com, by selecting “Investors” / “News” / “IR Calendar.”A replay of the conference call will be available shortly after completion of the call until May 28, 2020, by calling (877) 660-6853, or (201) 612-7415 if calling...

TORONTO, May 07, 2020 (GLOBE NEWSWIRE) — Compass Gold Corp. (TSX-V: CVB) (Compass or the Company) is pleased to provide an update on the recently completed drilling and ongoing shallow soil geochemistry exploration work at the Tarabala and Sodala prospect areas, located on the Company’s Sikasso Property in Southern Mali (Figure 1).HighlightsAir core (AC) drilling at Tarabala (26 RC holes, 1,435 m) intersected gold mineralization within the 10-km long Tarabala soil geochemistry trendBest interval at Tarabala was 16 m at 1.51 g/t Au (from 16 m), including 4 m @ 5.20 g/t Au (from 26m)Drilling at the Sodala artisanal workings intersected NE-trending structure containing five narrow gold zones in one hole (SAAC031), including 1 m at 2.71 g/t Au (from 16 m)An AC drill program of at least 2,500 m will commence immediately, starting with...

$40.3 million revenue$5.0 million net income$17.8 million EBITDANo significant debt maturities until 2023MONACO, May 07, 2020 (GLOBE NEWSWIRE) — Navios Maritime Containers L.P. (“Navios Containers” or the “Company”) (NASDAQ: NMCI), a growth vehicle dedicated to the container sector of the maritime industry, today reported its financial results for the first quarter ended March 31, 2020.Angeliki Frangou, Chairman and Chief Executive Officer, stated, “While the humanitarian crises caused by the pandemic has been heart breaking, we have also been strengthened by the courage and compassion of the first responders, particularly the many dedicated health care workers. At any given time, our vessels carry about 1,000 people. Keeping these people safe and these vessels moving in and out of quarantined countries, with ever-changing...

RAMSEY, N.J. and BOCA RATON, Fla., May 07, 2020 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immuno-deficient patients at risk for infection and others at risk for certain infectious diseases, today announced several recent corporate achievements pertaining to its supply chain robustness objectives as established at the beginning of 2020.“We have been very active during these challenging times in executing upon what we believe to be high value-added improvements to our supply chain to enhance robustness, increase capacity and heighten control over the production of our products.  These achievements include the successful manufacturing of three BIVIGAM®...